Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2019

View Archived Issues

ADC traffic rules revealed

Dystrophy mutation protects cells from HIV infection

An organoid model for prenatal brain development

Potent AXL kinase inhibitor with promising in vitro and in vivo biological activity

CAD-1883 demonstrates promising safety in phase I study

Circulating galectin-1 as a predictive biomarker of CAD and MACE in patients with stable angina

FDA grants IND approval for HH-2710

Patient enrollment ongoing in phase I study of Debio-0123

Phase III CheckMate-548 study does not meet one of its primary endpoints

Bristol-Myers Squibb describes preclinical profile of apelin receptor agonist BMS-986224

New AAV gene therapy for mucopolysaccharidosis IVA

Acesion presents data on the selective negative allosteric SK channel modulator AP-30663

Zika vaccine averts dengue cross-reactive antibody responses

Discovery of indazole/indole derivatives acting as glucagon receptor antagonists

A novel preclinical model of cocaine and alcohol coabuse

Medshine Discovery divulges FGFR inhibitors

Merck & Co. describes HIV integrase inhibitors

European Commission approves Tecentriq for extensive-stage SCLC and non-squamous NSCLC

Sinovent presents new E-NPP 2 inhibitors

Adlai Nortye discloses adenosine A2A and/or A2B receptor antagonists

Universite de Liege discovers new antibacterials

European Commission approves Lonsurf for metastatic gastric cancer

China's NMPA approves Focus V for third-line treatment of SCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...